dotMD.com
Find a Doctor
✓ Translated by DotMD AI Clinical Council Source: ClinicalTrials.gov Registry (NIH NLM) • Completed Human Clinical Trial (NCT)
Verify Primary Source: NIH PubMed PMID #NCT02081092
Plain-English Research Story • 8th-Grade Reading Level

Can This Approach Help? Inside the Latest Research on Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short

The purpose of this study is twofold: to assess routine cat scan (CT) imaging as a biomarker for removal of lipoprotein surfactant via lung lavage (where CT is the gold-standard imaging technique for density quantification), and to utilize

Original Paper Title: “Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT” (ClinicalTrials.gov Registry (NIH NLM), 2018-10-29)

Elena Rostova (AI Quant) Rigor Score
89 / 100
Sample Size (Participants)
N = 9
Evidence Classification
Completed Human Clinical Trial (NCT)
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The Bottom-Line Finding: This study will also serve to generate baseline scanning that may aid in developing analytical tools to evaluate and treat specific lung regions of patients with PAP.
  • Who Was Studied: Completed Human Clinical Trial (NCT) published in ClinicalTrials.gov Registry (NIH NLM) following 9 real-world participants.
  • Strength of the Evidence: Earned a 89/100 Study Rigor Score based on trial design, sample size, and peer-reviewed controls.
  • Smart Next Step: Share this plain-English summary with your doctor or pharmacist before starting, stopping, or changing any treatment.
The Full Story in Plain English

What the Study Found (In Plain English)

The purpose of this study is twofold: to assess routine cat scan (CT) imaging as a biomarker for removal of lipoprotein surfactant via lung lavage (where CT is the gold-standard imaging technique for density quantification), and to utilize a novel UTE MRI protocol to similarly quantify surfactant removal. This study will also serve to generate baseline scanning that may aid in developing analytical tools to evaluate and treat specific lung regions of patients with PAP. Registered in the U.S. National Library of Medicine ClinicalTrials.gov v2 registry (NCT02081092).

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Published in ClinicalTrials.gov Registry (NIH NLM) (2018-10-29) • Study Design: Completed Human Clinical Trial (NCT) • Participants: N = 9 • Biostatistical Rigor Score: 89/100. Primary Takeaway: This study will also serve to generate baseline scanning that may aid in developing analytical tools to evaluate and treat specific lung regions of patients with PAP.

Study Limitations & Caveats Before You Act

While this completed human clinical trial (nct) scored 89/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.

Formal Peer-Reviewed Study Reference
“Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT”
Published in ClinicalTrials.gov Registry (NIH NLM) (2018-10-29) • PMID/ID: NCT02081092
Read Formal Study
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID NCT02081092: Can This Approach Help? Inside the Latest Research on Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short

3 of 3 Free Questions Remaining